MedTrace Logo

ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking

NCT00808015 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1373

Last updated 2015-05-12

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to describe the characteristics of the smoker who wants to quit and his/her treating physician, in addition to determine the safety and effectiveness of Champix in the real-world setting of smokers in routine clinical practice.

Conditions

  • Smoking Cessation

Interventions

DRUG

varenicline

Champix will be prescribed as per usual practice and at the sole discretion of the physician

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-02-28
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • China
  • India
  • Philippines
  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00808015 on ClinicalTrials.gov